GSK plc (NYSE:GSK) Shares Sold by Laird Norton Wetherby Wealth Management LLC

Laird Norton Wetherby Wealth Management LLC trimmed its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 31.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,447 shares of the pharmaceutical company's stock after selling 11,992 shares during the period. Laird Norton Wetherby Wealth Management LLC's holdings in GSK were worth $894,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of GSK. Fiduciary Alliance LLC purchased a new position in shares of GSK during the 4th quarter worth approximately $390,000. Brookstone Capital Management increased its stake in shares of GSK by 19.8% during the 4th quarter. Brookstone Capital Management now owns 31,701 shares of the pharmaceutical company's stock worth $1,072,000 after purchasing an additional 5,244 shares in the last quarter. Marcum Wealth LLC boosted its position in GSK by 6.7% during the fourth quarter. Marcum Wealth LLC now owns 9,366 shares of the pharmaceutical company's stock worth $317,000 after acquiring an additional 591 shares during the last quarter. San Luis Wealth Advisors LLC boosted its position in GSK by 37.8% during the fourth quarter. San Luis Wealth Advisors LLC now owns 21,968 shares of the pharmaceutical company's stock worth $743,000 after acquiring an additional 6,031 shares during the last quarter. Finally, Advisors Management Group Inc. ADV boosted its position in GSK by 6.1% during the fourth quarter. Advisors Management Group Inc. ADV now owns 91,530 shares of the pharmaceutical company's stock worth $3,096,000 after acquiring an additional 5,259 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on GSK shares. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, BNP Paribas started coverage on shares of GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and an average target price of $40.58.

GSK Trading Up 0.6%

Shares of GSK traded up $0.24 during mid-day trading on Tuesday, reaching $38.20. The company had a trading volume of 1,191,514 shares, compared to its average volume of 4,833,247. The stock has a market cap of $78.81 billion, a price-to-earnings ratio of 24.02, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The firm has a fifty day simple moving average of $37.37 and a 200-day simple moving average of $35.96. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.80. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the business earned $0.43 EPS. On average, sell-side analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be issued a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.42%. The ex-dividend date of this dividend is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.